• M. D. B. Stephens


Adverse drug reactions (ADR) must have started at the dawn of time when man first used plants as medication and learnt to brew alcohol and smoke tobacco. Both Homer (700 BC) and Hippocrates (400 BC) referred to them as problems. The history of ADR before thalidomide has been covered by Penn in Iatrogenic Diseases (see Bibliography).


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Distillers Company (Biochemicals Ltd). Distaval. Lancet, 1961, 2, 1262Google Scholar
  2. *2.
    Nicholls, J.J. The Practolol Syndrome — a retrospective analysis. In Postmarketing Surveillance of Adverse Reactions to New Medicines. Medico-pharmaceutical Forum, Publication no. 7, 1977Google Scholar
  3. 3.
    Anon. Thalidomide’s long shadow. Br. Med. J., 1976, 2, 1155Google Scholar
  4. *4.
    Skegg, D.C.G. and Doll, R. The case for recording events in clinical trials. Br. Med. J., 1977, 2, 1523–1524CrossRefGoogle Scholar
  5. 5.
    Hemminki, L. Study of information submitted by drug companies to licensing authorities. Br. Med. J., 1980, 1, 836Google Scholar
  6. 6.
    Skegg, D.C.G. Adverse reaction monitoring in the future. In Pharmaceutical Medicine (ed. N. Macleod), Churchill Livingstone, 1979, p.144Google Scholar
  7. 7.
    Dollery, C.T. Clinical trials of new drugs. J.R. Coll. Physicians Lond., 1977, 11(3), 226–233Google Scholar
  8. 8.
    Inman, W.H.W. Monitoring by voluntary reporting at national level. In Adverse Drug Reactions (ed. D.J. Richards and R.K. Rondel), Churchill Livingstone, 1972Google Scholar
  9. 9.
    Inman, W.H.W. and Adelstein, A.M. Rise and fall of asthma mortality in England and Wales in relation to pressurised aerosols. Lancet, 1969, 2, 279CrossRefGoogle Scholar
  10. 10.
    Crooks, J. The detection of adverse drug reactions. J.R. Coll. Physicians Lond., 1977, 11(3), 239–244Google Scholar
  11. 11.
    Tierney, S. The testing of new drugs and the responsibility for their unforeseen effects. J.R. Coll. Physicians Lond., 1977, 11(3), 237Google Scholar
  12. 12.
    Beral, V. et al. Mortality among oral contraceptive users. Lancet, 1977, 2, 727–731Google Scholar
  13. 13.
    Bader, J.-P. Scrip, 1981, No. 639, 1Google Scholar
  14. 14.
    Schönhöfer, P. Scrip, 1981, No. 638, 2Google Scholar
  15. 15.
    Melmon, K.L. and Nierenberg, D.W. Drug interactions and the prepared observer. New Engl. J. Med., 1981, 304(12), 723–725CrossRefGoogle Scholar
  16. 16.
    Wright, P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br. Med. J., 1975, 1, 595–598CrossRefGoogle Scholar
  17. 17.
    Herbst, A.L., Ulfelder, H. and Poskanzer, D.C. Association of maternal stilboestrol therapy with tumour appearance in young women. New Engl. J. Med., 1971, 284, 878CrossRefGoogle Scholar
  18. 18.
    Committee of Principal Investigators. A co-operative trial in the primary prevention of ischaemic heart disease using Clofibrate. Br. Heart J., 1978, 40, 1069–1118CrossRefGoogle Scholar
  19. 19.
    Committee of Principal Investigators. WHO co-operative trial on primary prevention of ischaemic heart disease using Clofibrate to lower serum cholestrol: Mortality follow-up. Lancet, 1980, 2, 279–385Google Scholar
  20. 20.
    Cross. K.W. Cost of preventing retrolental fibroplasia. Lancet, 1973, 2, 954–956CrossRefGoogle Scholar
  21. 21.
    Bolton, D.P.G. and Cross, K.W. Further observations on cost of preventing retrolental fibroplasia. Lancet, 1974, 1, 445–458CrossRefGoogle Scholar
  22. 22.
    Miller, D.L., Ross, E.M., Alderslade, R., Bellman, M.H. and Rawson, N.S.B. Pertussis immunisation and serious acute neurological illness in children. Br. Med. J., 1981, 282(6276), 1565CrossRefGoogle Scholar
  23. 23.
    Meade, T.W. Pertussis vaccine. Br. Med. J., 1981, 283, 59CrossRefGoogle Scholar
  24. 24.
    Anon. Pertussis vaccine. Br. Med. J., 1981, 282(6276), 1563–1564Google Scholar
  25. 25.
    Fleming, D.M., Knox, J.D.E. and Crombie, D.L. Debendox in early pregnancy and fetal malformation. Br. Med. J., 1981, 283, 99–101CrossRefGoogle Scholar
  26. 26.
    Dinman, B.D. Occupational health and the reality of risk — an eternal dilemma of tragic choice. J. Occup. Med., 1980, 22(3), 153–157Google Scholar
  27. 27.
    Dinman, B.D. The reality and acceptance of risk. J.A.M.A., 1980, 244(11), 1226–1228CrossRefGoogle Scholar
  28. 28.
    Daily Telegraph. 3 June–25 June 1981Google Scholar
  29. 29.
    Pochin, E.E. The acceptance of risk. Br. Med. Bull., 31(3), 1975, 184Google Scholar
  30. 30.
    Porter, J. and Jick, H., Drug-related deaths among medical in-patients. J.A.M.A., 1977, 237, 879CrossRefGoogle Scholar
  31. 31.
    Girdwood, R.H. Deaths after taking medicaments. Br. Med. J., 1974, 1, 501–504CrossRefGoogle Scholar
  32. 32.
    Anon. Hunting rare adverse drug reactions. Br. Med. J., 1981, 282(6261), 342Google Scholar
  33. *33.
    Inman, W.H.W. Postmarketing surveillance of adverse drug reactions in general practice, I. Br. Med. J., 1981, 282, 1131–1132CrossRefGoogle Scholar
  34. 34.
    Shapiro, S. Postmarketing assessment of drugs. In Post-marketing Surveillance of Adverse Reactions to New Medicines, Medico-pharmaceutical Forum, Publication no. 7, 1977Google Scholar
  35. *35.
    Lewis, J.A. Postmarketing surveillance: How many patients? Trends Pharmacol. Sci., 1981, 2(4), 93–94CrossRefGoogle Scholar
  36. 36.
    Anon. Rauwolfia and breast cancer. Lancet, 1975, 2, 312Google Scholar
  37. 37.
    Spriet-Pourra, C., Spriet, A., Soubrie, C. and Simon, P. Les méthodes d’étude des effets indésirables des médicaments, II: Thérapie, 1982, 37, 13–22Google Scholar
  38. *38.
    Finney, D.J. The design and logic of a monitor of drug use. J. Chron. Dis., 1965, 18, 77–98CrossRefGoogle Scholar
  39. *39.
    Inman, W.H.W. Postmarketing surveillance of adverse drug reactions in general practice, II. Br. Med. J., 1981, 282Google Scholar
  40. 40.
    Karch, F.E. and Lasagna, L. Adverse drug reactions. J.A.M.A., 1975, 234(12), 1236CrossRefGoogle Scholar
  41. 41.
    Division of Drug Experience, Food and Drug Administration. Procedural Manual for Handling Drug Experience Reports. Glossary, Paper flow and Algorithms, 1980Google Scholar
  42. *42.
    Kramer, M.S., Leventhal, J.M., Hutchinson, T.A. and Feinstein, A.R. An algorithm for the operational assessment of adverse drug reactions, I: Background, description for use and instruction. J.A.M.A., 1979, 242(7), 623–632CrossRefGoogle Scholar
  43. 43.
    Weintraub, M. Recording events in clinical trials. Br. Med. J., 1978, i, 581CrossRefGoogle Scholar
  44. 44.
    Simpson, R.J., Tiplady, B. and Skegg, D.C.G. Event recording in a clinical trial of a new medicine. Br. Med. J., 1980, 280, 1133–1134CrossRefGoogle Scholar
  45. 45.
    Anon. Lessons from the benoxaprofen affair. Lancet, 1982, 529Google Scholar
  46. 46.
    Seventh European Symposium on Clinical Pharmacological Evaluation in Drug Control, Deidesheim, 1978. WHO Euro Reports and Studies, WHO, Copenhagen, 13Google Scholar
  47. *47.
    Rawlins, M.D. and Thompson, J.W. Pathogenesis of adverse drug reactions. In Textbook of Adverse Drug Reactions (ed. D.M. Davies), Oxford University Press, 1977, pp. 10–31Google Scholar
  48. 48.
    Venulet, J. Monitoring adverse reactions to drugs. In Progress in Drug Research (ed. E. Jucken), Berghausen Verlag, Basle, 1977Google Scholar
  49. 49.
    Péré, J.C., Bégaud, B., Haramburu, F. and Albin, H. Notions de fréquence et de gravité des effets indésirables. Thérapie, 1984, 447–452Google Scholar
  50. 50.
    Enstellung von Monographie-Entwürfen. Pharm Ind., 1986, 48 (11a), 1293Google Scholar
  51. 51.
    Toogood, J.H. What do we mean by ‘usually’? Lancet, 1980, i, 1094CrossRefGoogle Scholar
  52. 52.
    Marion, M.H. and Simon, P. Signification des adverbes utilisés pour indiquer la fréquence des effets secondaires d’un médicament. Thérapie, 1984, 39, 47–63Google Scholar
  53. 53.
    Bennett, B.S. and Lipman, A.G. Comparative study of prospective surveillance and voluntary reporting in determining the incidence of adverse drug reactions. Am. J. Hosp. Pharm., 1977, 34, 931–936Google Scholar
  54. *54.
    Reidenberg, M.M. and Lowenthal, D.T. Adverse non-drug reactions. New Engl. J. Med., 1968, 279(13), 678–679CrossRefGoogle Scholar
  55. 55.
    Bulpitt, C.J., Dollery, C.T. and Carne, S. A symptom questionnaire for hypertensive patients. J. Chron. Dis., 1974, 27, 309–323CrossRefGoogle Scholar
  56. 56.
    Bulpitt, C.J., Dollery, C.T. and Carne, S. Change in symptoms of hypertensive patients after referral to hospital clinic. Br. Heart J., 1976, 38, 121–128CrossRefGoogle Scholar
  57. 57.
    Joubert, P.H., Van Rijssen, F.W.J. and Venter, J.P. Drug side effects assessed in a ‘naturalistic’ setting. S. Afr. Med. J., 1977, 52, 34–36Google Scholar
  58. 58.
    Joyce, C.R.B. Placebos and other comparative treatments. Br. J. Clin. Pharmacol., 1982, 13, 313–318CrossRefGoogle Scholar
  59. 59.
    Pogge, R.C. The toxic placebo. Med. Times, 1965, 91(8), 773–776Google Scholar
  60. 60.
    Wolf, S. Placebos. Ass. Res. Nerv. Dis. Proc., 1959, 37, 147–161Google Scholar
  61. 61.
    Wolf, S. Effects of suggestions and conditioning on the action of chemical agents in human subjects: the pharmacology of placebos. J. Clin. Invest., 1950, 29, 100CrossRefGoogle Scholar
  62. 62.
    Wolf, S. and Pinsky, R.H. Effects of placebo administration and occurrence of toxic reactions. J.A.M.A., 1954, 155, (4), 339–341CrossRefGoogle Scholar
  63. 63.
    Vinar, O. Dependence on a placebo: a case report. Br. J. Psychiat., 1969, 115, 1189–1190CrossRefGoogle Scholar
  64. 64.
    Domecq, C., Naranjo, C.A., Ruiz, I. and Busto, U. Sex-related variations in the frequency and characteristics of adverse drug reactions. J. Clin. Pharmacol. Ther. Toxicol., 1980, 18(8), 362–366Google Scholar
  65. 65.
    Green, D.M. Pre-existing conditions, placebo reactions and ‘side effects’. Ann. Intern. Med., 1964, 60(2), 255–265CrossRefGoogle Scholar
  66. 66.
    Letemendia, F.J.J. and Harris, A.D. The influence of side effects on the reporting of symptoms. Psychopharmacologia, 1959, 1, 39–17CrossRefGoogle Scholar
  67. 67.
    Wolf, S. The pharmacology of placebos. Pharmacol. Rev., 1959, 11, 689Google Scholar
  68. 68.
    Tucker, W.B. Effects of placebo administration and occurrence of toxic reactions, J.A.M.A., 1954, 155, 339CrossRefGoogle Scholar
  69. 69.
    Thompson, R. Side effects and placebo amplification. Brit. J. Psychiat., 1982, 140, 64–68CrossRefGoogle Scholar
  70. 70.
    Lasagna, L., Mosteller, F., Von Felsinger, J.M. and Beecher, H.K. A study of placebo response. Am. J. Med., 1954, 16, June, 770–779CrossRefGoogle Scholar
  71. 71.
    Knowles, J.B. and Lucas, C.J. Experimental studies of the placebo response. J. Ment. Sci., 1960, 106, 231–240Google Scholar
  72. 72.
    Beecher, H.K. The powerful placebo. J.A.M.A., 1955, 159, Dec, 1602–1606CrossRefGoogle Scholar
  73. 73.
    Lasagna, L., Laties, V.G. and Dohan, J.L. Further studies on the ‘pharmacology’ of placebo administration. J. Clin. Invest., 1958, 37, 533–537CrossRefGoogle Scholar
  74. 74.
    Fields, H.L. and Levine, J.D. Biology of placebo analgesia. Am. J. Med., 1981, 70(4), 745–746CrossRefGoogle Scholar
  75. 75.
    Levine, J.D., Gordon, N.C. and Fields, H.L. The mechanism of placebo analgesia. Lancet, 1978, 23, 654–657CrossRefGoogle Scholar
  76. 76.
    Leader. Lancet 1983, ii, 624Google Scholar
  77. 77.
    Posner, J., Burke, C.A. The effects of Naloxone on opiate and placebo analgesia in healthy volunteers. Psychopharmacology, 1985, 87, 468–472CrossRefGoogle Scholar
  78. 78.
    McDonald, C.J., Mazzuca, S.A. How much of the placebo effect is really statistical regression. Statistics in Medicine, 1983, 2, 417–427CrossRefGoogle Scholar
  79. 79.
    Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. New Engl. J. Med., 1981, 304(14), 801–807CrossRefGoogle Scholar
  80. *80.
    Schindel, L. Placebo-induced side effects. In Drug Induced Diseases (ed. L. Meyler and H.M. Peck), Excerpta Medica, AmsterdamGoogle Scholar

Copyright information

© M.D.B. Stephens 1988

Authors and Affiliations

  • M. D. B. Stephens

There are no affiliations available

Personalised recommendations